A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1× · see citing works

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742 · see citing works

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674 · see citing works

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,288 · see citing works

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137 · see citing works

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037 · see citing works

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641 · see citing works

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541 · see citing works

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527 · see citing works

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 442 · see citing works

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7107e2 · Cited by 435 · see citing works

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Wu, K., Werner, A. P., Koch, M., Choi, A., Narayanan, E., Stewart-Jones, G. B. E., Colpitts, T., Bennett, H., Boyoglu-Barnum, S., Shi, W., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102179 · Cited by 409 · see citing works

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Thompson, M. G., Natarajan, K., Irving, S. A., Rowley, E. A., Griggs, E. P., Gaglani, M., Klein, N. P., Grannis, S. J., DeSilva, M. B., Stenehjem, E., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7104e3 · Cited by 398 · see citing works

Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination

Suryawanshi, R. K., Chen, I. P., Ma, T., Syed, A. M., Brazer, N., Saldhi, P., Simoneau, C. R., Ciling, A., Khalid, M. M., Sreekumar, B. K. N., et al. (2022) · Nature · doi:10.1038/s41586-022-04865-0 · Cited by 208 · see citing works

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

Chalkias, S., Eder, F. S., Essink, B. J., Khetan, S. K., Nestorova, B., Feng, J., Chen, X., Chang, Y., Zhou, H., Montefiori, D. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02031-7 · Cited by 130 · see citing works

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki, M., Barkati, S., Fafard, J., Talbot, D. C., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00578-3 · Cited by 109 · see citing works

Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Chu, L., Montefiori, D., Huang, W., Nestorova, B., Chang, Y., Carfi, A., Edwards, D. K., Oestreicher, J., Legault, H., Girard, B., et al. (2021) · doi:10.1101/2021.09.29.21264089 · Cited by 105 · see citing works

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infectionPreprint

Cao, Y., Yisimayi, A., Jian, F., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.30.489997 · Cited by 90 · see citing works

Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C

Tang, J., Novak, T., Hecker, J., Grubbs, G., Zahra, F. T., Bellusci, L., Pourhashemi, S., Chou, J. S., Moffitt, K. L., Halasa, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30649-1 · Cited by 55 · see citing works

Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022

Prasad, N., Derado, G., Nanduri, S. A., Reses, H. E., Dubendris, H., Wong, E., Soe, M. M., Li, Q., Dollard, P., Bagchi, S., et al. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7118a4 · Cited by 43 · see citing works

Multiple Endpoints in Clinical Trials

Weissfeld, L. A. (2014) · Wiley StatsRef: Statistics Reference Online · doi:10.1002/9781118445112.stat04948 · Cited by 33 · see citing works

mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children

Girard, B., Tomassini, J. E., Deng, W., Maglinao, M., Zhou, H., Figueroa, A., Ghamloush, S. S., Montefiori, D. C., Das, R., & Pajon, R. (2022) · doi:10.1101/2022.01.24.22269666 · Cited by 23 · see citing works

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccinePreprint

Chalkias, S., Eder, F. S., Essink, B. J., Khetan, S. K., Nestorova, B., Feng, J., Chen, X., Chang, Y., Zhou, H., Montefiori, D. C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1555201/v1 · Cited by 22 · see citing works

Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant SurgePreprint

Baden, L. R., Sahly, H. M. E., Essink, B. J., Follmann, D. A., Neuzil, K. M., August, A., Clouting, H., Fortier, G., Deng, W., Han, S., et al. (2021) · medRxiv · doi:10.1101/2021.09.17.21263624 · Cited by 21 · see citing works

Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults

Wilson, E. M. P., Goswami, J., Baqui, A. H., Doreski, P. A., Marc, G. P., Zaman, K., Monroy, J., Duncan, C. J. A., Ujiie, M., Rämet, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307079 · Cited by 517 · see citing works

Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission

Shrestha, L. B., Foster, C. S. P., Rawlinson, W. D., Tedla, N. T., & Bull, R. A. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2381 · Cited by 469 · see citing works

A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies

Chatterjee, S., Bhattacharya, M., Nag, S., Dhama, K., & Chakraborty, C. (2023) · Viruses · doi:10.3390/v15010167 · Cited by 313 · see citing works

Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity: A Systematic Review and Meta-analysis

Menegale, F., Manica, M., Zardini, A., Guzzetta, G., Marziano, V., d'Andrea, V., Trentini, F., Ajelli, M., Poletti, P., & Merler, S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10650 · Cited by 280 · see citing works

Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

Davis-Gardner, M. E., Lai, L., Wali, B., Samaha, H., Solis, D., Lee, M., Morrison-Porter, A., Hentenaar, I., Yamamoto, F. F., Godbole, S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2214293 · Cited by 254 · see citing works

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

Park, Y., Pinto, D., Walls, A. C., Liu, Z., Marco, A. D., Benigni, F., Zatta, F., Silacci-Fregni, C., Bassi, J., Sprouse, K. R., et al. (2022) · Science · doi:10.1126/science.adc9127 · Cited by 225 · see citing works

Strategies to reduce the risks of mRNA drug and vaccine toxicity

Bitounis, D., Jacquinet, E., Rogers, M. A., & Amiji, M. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00859-3 · Cited by 237 · see citing works

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters

Collier, A.-R. Y., Miller, J. J., Hachmann, N. P., McMahan, K., Liu, J., Bondzie, E. A., Gallup, L., Rowe, M., Schonberg, E., Thai, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2213948 · Cited by 225 · see citing works

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster

Wang, Q., Bowen, A. D., Valdez, R., Gherasim, C., Gordon, A. L., Liu, L., & Ho, D. D. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2213907 · Cited by 198 · see citing works

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice

Scheaffer, S. M., Lee, D., Whitener, B., Ying, B., Wu, K., Liang, C.-Y., Jani, H., Martin, P., Amato, N. J., Avena, L. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02092-8 · Cited by 169 · see citing works

Mapping SARS-CoV-2 antigenic relationships and serological responses

Wilks, S. H., Mühlemann, B., Shen, X., Türeli, S., LeGresley, E. B., Netzl, A., Caniza, M. A., Chacaltana-Huarcaya, J. N., Corman, V. M., Daniell, X. G., et al. (2023) · Science · doi:10.1126/science.adj0070 · Cited by 134 · see citing works

Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study

Arbel, R., Peretz, A., Sergienko, R., Friger, M., Beckenstein, T., Duskin-Bitan, H., Yaron, S., Hammerman, A., Bilenko, N., & Netzer, D. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00122-6 · Cited by 145 · see citing works

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines

Lee, J., Woodruff, M. C., Kim, E. H., & Nam, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00999-x · Cited by 137 · see citing works

Durability of immune response after COVID-19 booster vaccination and association with COVID-19 omicron infection

Gilboa, M., Regev-Yochay, G., Mandelboim, M., Indenbaum, V., Asraf, K., Fluss, R., Amit, S., Mendelson, E., Doolman, R., Afek, A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31778 · Cited by 128 · see citing works

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

Chalkias, S., Eder, F. S., Essink, B. J., Khetan, S. K., Nestorova, B., Feng, J., Chen, X., Chang, Y., Zhou, H., Montefiori, D. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02031-7 · Cited by 130 · see citing works

Clinical delivery of circular RNA: Lessons learned from RNA drug development

Young, T. L., Wang, K. C., Varley, A., & Li, B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114826 · Cited by 126 · see citing works

Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans

Tortorici, M. A., Addetia, A., Seo, A. J., Brown, J. T., Sprouse, K., Logue, J., Clark, E., Franko, N., Chu, H. Y., & Veesler, D. (2024) · Immunity · doi:10.1016/j.immuni.2024.02.016 · Cited by 124 · see citing works

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years

Winokur, P., Gayed, J., Fitz-Patrick, D., Thomas, S. J., Diya, O., Lockhart, S., Xu, X., Zhang, Y., Bangad, V., Schwartz, H. I., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213082 · Cited by 116 · see citing works

Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

Mackin, S., Desai, P., Whitener, B. M., Karl, C. E., Liu, M., Baric, R. S., Edwards, D. K., Chicz, T. M., McNamara, R. P., Alter, G., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01359-1 · Cited by 114 · see citing works

Predicting the efficacy of variant-modified COVID-19 vaccine boosters

Khoury, D. S., Docken, S. S., Subbarao, K., Kent, S. J., Davenport, M. P., & Cromer, D. (2023) · Nature Medicine · doi:10.1038/s41591-023-02228-4 · Cited by 102 · see citing works

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

Tenforde, M. W., Weber, Z. A., Natarajan, K., Klein, N. P., Kharbanda, A. B., Stenehjem, E. A., Embí, P. J., Reese, S. E., Naleway, A. L., Grannis, S. J., et al. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm715152e1 · Cited by 104 · see citing works

Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens

Fang, Z., Monteiro, V. S., Renauer, P. A., Shang, X., Suzuki, K., Ling, X., Bai, M., Xiang, Y., Levchenko, A., Booth, C. J., et al. (2023) · Cell Research · doi:10.1038/s41422-023-00792-5 · Cited by 94 · see citing works

Frameworks for transformational breakthroughs in RNA-based medicines

Androsavich, J. R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00943-2 · Cited by 93 · see citing works

In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms

Cankat, S., Demael, M. U., & Swadling, L. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01116-8 · Cited by 84 · see citing works

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Rössler, A., Netzl, A., Knabl, L., Schäfer, H., Wilks, S., Bante, D., Falkensammer, B., Borena, W., von Laer, D., Smith, D. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35312-3 · Cited by 77 · see citing works

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats

Echaide, M., Chocarro, L., Bocanegra, A., Blanco, E., Kochan, G. T., & Escors, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065944 · Cited by 82 · see citing works

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study

Andersson, N. W., Thiesson, E. M., Baum, U., Pihlström, N., Starrfelt, J., Faksová, K., Poukka, E., Meijerink, H., Ljung, R., & Hviid, A. P. (2023) · BMJ · doi:10.1136/bmj-2022-075286 · Cited by 92 · see citing works

Global and regional genetic diversity of HIV-1 in 2010–21: systematic review and analysis of prevalence

Nair, M. S., Gettins, L., Fuller, M., Kirtley, S., & Hemelaar, J. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00151-4 · Cited by 76 · see citing works

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02517-y · Cited by 73 · see citing works

Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy

Reynolds, G. K., Hall, V. G., & Teh, B. W. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14109 · Cited by 69 · see citing works

Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history

Wang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R. A., Coggins, S. A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.012 · Cited by 59 · see citing works

Immune imprinting and next-generation coronavirus vaccines

Huang, C. Q., Vishwanath, S., Carnell, G., Chan, A. C. Y., & Heeney, J. L. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01505-9 · Cited by 66 · see citing works

Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

Wang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R., Coggins, S., et al. (2022) · doi:10.1101/2022.07.05.498883 · Cited by 68 · see citing works

An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial

Saraf, A., Gurjar, R., Kaviraj, S., Kulkarni, A., Kumar, D., Kulkarni, R., Virkar, R., Krishnan, J., Yadav, A., Baranwal, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02955-2 · Cited by 66 · see citing works

Safety and Immunogenicity of XBB.1.5-Containing mRNA VaccinesPreprint

Chalkias, S., McGhee, N., Whatley, J. L., Essink, B. J., Brosz, A. B., Tomassini, J. E., Girard, B., Wu, K., Edwards, D. K., Nasir, A., et al. (2023) · medRxiv · doi:10.1101/2023.08.22.23293434 · Cited by 66 · see citing works

Defending against SARS-CoV-2: The T cell perspective

Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 64 · see citing works

Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines

Russell, C. A., Fouchier, R. A. M., Ghaswalla, P. K., Park, Y., Vicic, N., Ananworanich, J., Nachbagauer, R., & Rudin, D. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2336357 · Cited by 69 · see citing works

Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study

Kirsebom, F. C. M., Andrews, N. J., Stowe, J., Ramsay, M. E., & Bernal, J. L. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00365-1 · Cited by 63 · see citing works

Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines

Fraser, R., Resendiz, A. O., Mazein, A., & Dockrell, D. H. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.01.003 · Cited by 61 · see citing works

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Branche, A. R., Rouphael, N., Diemert, D. J., Falsey, A. R., Losada, C., Baden, L. R., Frey, S. E., Whitaker, J. A., Little, S. J., Anderson, E. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02503-4 · Cited by 61 · see citing works

Evolution of antibody immunity following Omicron BA.1 breakthrough infection

Kaku, C. I., Starr, T. N., Zhou, P.-P., Dugan, H. L., Khalifé, P., Song, G., Champney, E. R., Mielcarz, D. W., Geoghegan, J. C., Burton, D. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38345-4 · Cited by 65 · see citing works

Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

Surie, D., Bonnell, L., Adams, K., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7142a3 · Cited by 59 · see citing works

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

(2023) · doi:10.1038/s41467-023-36566-1 · Cited by 59 · see citing works

T cell immune memory after covid-19 and vaccination

Wang, L., Nicols, A. R., Turtle, L. C. W., Richter, A. G., Duncan, C. J. A., Dunachie, S. J., Klenerman, P., & Payne, R. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000468 · Cited by 61 · see citing works

Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period

Ao, D., He, X., Liu, J., & Xu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01724-w · Cited by 58 · see citing works

Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines

Chalkias, S., McGhee, N., Whatley, J. L., Essink, B. J., Brosz, A. B., Tomassini, J. E., Girard, B., Edwards, D. K., Wu, K., Nasir, A., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae067 · Cited by 56 · see citing works

School closures during COVID-19: an overview of systematic reviews

Hume, S., Brown, S. R., & Mahtani, K. R. (2023) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2022-112085 · Cited by 50 · see citing works

Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bethune, C., Nally, R., Bula, M., Kalra, P. A., Clark, R., Dargan, P. I., Boffito, M., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00295-5 · Cited by 50 · see citing works

Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study

Tan, C. Y., Chiew, C. J., Pang, D., Lee, V. J., Ong, B. K. C., Wang, L., Ren, E. C., Lye, D. C., & Tan, K. B. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00373-0 · Cited by 50 · see citing works

Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses

Wang, C. Y., Peng, W., Kuo, B.-S., Ho, Y.-H., Wang, M.-S., Yang, Y.-T., Chang, P.-Y., Shen, Y.-H., & Hwang, K. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1010870 · Cited by 48 · see citing works

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Chalkias, S., Harper, C., Vrbicky, K. W., Walsh, S. R., Essink, B. J., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38892-w · Cited by 48 · see citing works

When to update COVID-19 vaccine composition

Grant, R., Sacks, J. A., Abraham, P., Chunsuttiwat, S., Cohen, C., Figueroa, J. P., Fleming, T. R., Fine, P., Goldblatt, D., Hasegawa, H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02220-y · Cited by 47 · see citing works

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

Tenforde, M. W., Weber, Z. A., Natarajan, K., Klein, N. P., Kharbanda, A. B., Stenehjem, E. A., Embí, P. J., Reese, S. E., Naleway, A. L., Grannis, S. J., et al. (2023) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7153a1 · Cited by 46 · see citing works

Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection

Ying, B., Darling, T. L., Desai, P., Liang, C.-Y., Dmitriev, I. P., Soudani, N., Bricker, T. L., Kashentseva, E. A., Harastani, H., Raju, S., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01743-x · Cited by 49 · see citing works

COVID-19 Booster Dose Vaccination Coverage and Factors Associated with Booster Vaccination among Adults, United States, March 2022

Lu, P.-J., Srivastav, A., Vashist, K., Black, C. L., Kriss, J. L., Hung, M.-C., Meng, L. M., Zhou, T., Yankey, D., Masters, N. B., et al. (2023) · Emerging infectious diseases · doi:10.3201/eid2901.221151 · Cited by 45 · see citing works

Broad-spectrum pan-genus and pan-family virus vaccines

Tan, C. W., Valkenburg, S., Poon, L. L. M., & Wang, L. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.05.017 · Cited by 41 · see citing works

Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines

Spinardi, J., & Srivastava, A. K. (2023) · Biomedicines · doi:10.3390/biomedicines11020370 · Cited by 44 · see citing works

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection

Yang, H. J., Hong, W., Hong, L., He, C., Lei, W., Zhou, Y., Zhao, T., Alu, A., Ma, X., Li, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01495-4 · Cited by 44 · see citing works

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography

Rössler, A., Netzl, A., Knabl, L., Bante, D., Wilks, S. H., Borena, W., von Laer, D., Smith, D. J., & Kimpel, J. (2023) · Nature Communications · doi:10.1038/s41467-023-41049-4 · Cited by 45 · see citing works

Fast-evolving COVID variants complicate vaccine updates

Callaway, E. (2022) · Nature · doi:10.1038/d41586-022-01771-3 · Cited by 43 · see citing works

Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020–2022

Marra, A. R., Sampaio, V. D. S., Ozahata, M. C., Lopes, R., Brito, A. F., Bragatte, M. A. D. S., Kalil, J. E., Miraglia, J. L., Malheiro, D. T., Guozhang, Y., et al. (2023) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2023.95 · Cited by 42 · see citing works

Timing of elective surgery and risk assessment after SARS‐CoV‐2 infection: 2023 update

El‐Boghdadly, K., Cook, T. M., Goodacre, T., Kua, J., Denmark, S., Mercer, N. S. G., Moonesinghe, R., & Summerton, D. J. (2023) · Anaesthesia · doi:10.1111/anae.16061 · Cited by 42 · see citing works

Efficacy of smallpox vaccines against Mpox infections in humans

Christodoulidou, M. M., & Mabbott, N. A. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad020 · Cited by 44 · see citing works

Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shotPreprint

Wang, Q., Bowen, A. D., Valdez, R., Gherasim, C., Gordon, A. L., Liu, L., & Ho, D. D. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.22.513349 · Cited by 41 · see citing works

AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans

Grigoryan, L., Feng, Y., Bellusci, L., Lai, L., Wali, B., Ellis, M. L., Yuan, M., Arunachalam, P. S., Hu, M., Kowli, S., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi8039 · Cited by 43 · see citing works

A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2

Jia, Z., Wang, K., Xie, M., Wu, J., Hu, Y., Zhou, Y., Yisimayi, A., Fu, W., Wang, L., Liu, P., et al. (2024) · Protein & Cell · doi:10.1093/procel/pwae033 · Cited by 40 · see citing works

Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting

Jeger‐Madiot, R., Planas, D., Staropoli, I., Debarnot, H., Kervevan, J., Mary, H., Collina, C., Fonseca, B. F., Robinot, R., Gellenoncourt, S., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240289 · Cited by 41 · see citing works

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial

Chalkias, S., Dennis, P., Petersen, D., Radhakrishnan, K., Vaughan, L. B., Handforth, R., Rossi, A., Wahid, R., Edwards, D. K., Feng, J., et al. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00236-1 · Cited by 38 · see citing works

Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management

Chavda, V. P., Balar, P. C., Vaghela, D. A., Solanki, H., Vaishnav, A., Hala, V., & Vora, L. K. (2023) · Vaccines · doi:10.3390/vaccines11010160 · Cited by 37 · see citing works

Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial

Tan, N. H., Geers, D., Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Bogers, S., van Dijk, L. L. A., Gommers, L., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00140-8 · Cited by 37 · see citing works

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases

Baden, L. R., Sahly, H. M. E., Essink, B. J., Follmann, D. A., Hachigian, G., Strout, C. B., Overcash, J. S., Doblecki‐Lewis, S., Whitaker, J. A., Anderson, E. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50376-z · Cited by 37 · see citing works

Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial

Goswami, J., Cardona, J. F., Hsu, D. C., Simorellis, A. K., Wilson, L. A., Dhar, R., Tomassini, J. E., Wang, X., Kapoor, A., Collins, A., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00589-9 · Cited by 37 · see citing works

Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach

Hogan, A. B., Doohan, P., Wu, S. L., Mesa, D. O., Toor, J., Watson, O. J., Winskill, P., Charles, G. D., Barnsley, G., Riley, E. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39736-3 · Cited by 35 · see citing works

mRNA vaccines against respiratory viruses

Whitaker, J. A., Sahly, H. M. E., & Healy, C. M. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000948 · Cited by 38 · see citing works

Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies

Song, S., Madewell, Z. J., Liu, M., Longini, I. M., & Yang, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1195908 · Cited by 34 · see citing works

The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review

Sarkar, A., Omar, S., Alshareef, A. H., Fanous, K., Sarker, S., Alroobi, H., Zamir, F., Yousef, M., & Zakaria, D. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2212568 · Cited by 34 · see citing works

Immune imprinting: The persisting influence of the first antigenic encounter with rapidly evolving viruses

Maltseva, M., Keeshan, A., Cooper, C., & Langlois, M. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2384192 · Cited by 33 · see citing works

Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages

Wang, Y., Long, Y., Wang, F., Li, C., & Liu, W. Y. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.79116 · Cited by 33 · see citing works

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections

Chemaitelly, H. S., Ayoub, H. H., AlMukdad, S., Faust, J. S., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., et al. (2023) · Journal of Travel Medicine · doi:10.1093/jtm/taad106 · Cited by 32 · see citing works

Immune Imprinting and Implications for COVID-19

Zhou, Z., Barrett, J., & He, X. (2023) · Vaccines · doi:10.3390/vaccines11040875 · Cited by 31 · see citing works

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

Springer, D. N., Bauer, M. W., Medits, I., Camp, J. V., Aberle, S. W., Burtscher, C., Höltl, E., Weseslindtner, L., Stiasny, K., & Aberle, J. H. (2023) · npj Vaccines · doi:10.1038/s41541-023-00708-9 · Cited by 32 · see citing works

A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants

Song, S., Madewell, Z. J., Liu, M., Yu, M., Xiang, S., Huo, Y., Sarkar, S., Chowdhury, A., Longini, I. M., & Yang, Y. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.049 · Cited by 32 · see citing works

An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants

Mambelli, F., de Araujo, A. C. V. S. C., Farias, J. P., de Andrade, K. Q., Ferreira, L. C. D. S., Minoprio, P. M. C., Leite, L. C. C., & Oliveira, S. C. (2025) · Pathogens · doi:10.3390/pathogens14010023 · Cited by 32 · see citing works

Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countriesPreprint

Andersson, N. W., Thiesson, E. M., Baum, U., Pihlström, N., Starrfelt, J., Faksová, K., Poukka, E., Meijerink, H., Ljung, R., & Hviid, A. P. (2023) · medRxiv · doi:10.1101/2023.01.19.23284764 · Cited by 31 · see citing works

Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults

Kopel, H., Nguyễn, V. H., Boileau, C., Bogdanov, A., Winer, I. H., Ducruet, T., Zeng, N., Bonafede, M., Esposito, D. B., Martin, D., et al. (2023) · Vaccines · doi:10.3390/vaccines11111711 · Cited by 30 · see citing works

Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift

Song, G., Yuan, M., Liu, H., Capozzola, T., Lin, R. N., Torres, J. L., He, W., Musharrafieh, R., Dueker, K., Zhou, P.-P., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115948 · Cited by 29 · see citing works

Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study

Yamin, D., Yechezkel, M., Arbel, R., Beckenstein, T., Sergienko, R., Duskin‐Bitan, H., Yaron, S., Peretz, A., Netzer, D., & Shmueli, E. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00207-4 · Cited by 30 · see citing works

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates

Routhu, N. K., Stampfer, S. D., Lai, L., Akhtar, A., Tong, X., Yuan, D., Chicz, T. M., McNamara, R. P., Jakkala, K., Davis-Gardner, M. E., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg7015 · Cited by 27 · see citing works

Structural Immunology of SARS ‐ CoV ‐2

Yuan, M., & Wilson, I. A. (2024) · Immunological Reviews · doi:10.1111/imr.13431 · Cited by 28 · see citing works

SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesPreprint

Branche, A. R., Rouphael, N., Diemert, D. J., Falsey, A. R., Losada, C., Baden, L. R., Frey, S. E., Whitaker, J. A., Little, S. J., Anderson, E. J., et al. (2022) · medRxiv · doi:10.1101/2022.07.12.22277336 · Cited by 29 · see citing works

Towards a post-pandemic future for global pathogen genome sequencing

Ladner, J. T., & Sahl, J. W. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002225 · Cited by 26 · see citing works

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial

Hannawi, S., Eldin, L. S., Abuquta, A., Alamadi, A., Mahmoud, S., Hassan, A., Liu, D., Yan, L., & Xie, L. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104386 · Cited by 27 · see citing works

Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis

Huth, L., Schäfer, L., Almanzar, G., Lupoli, G., Bischof, M. L., Wratil, P. R., Stövesand, T., Drechsler, C., Keppler, O. T., & Prelog, M. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2216309 · Cited by 27 · see citing works

Emergence of COVID-19 Variants: An Update

Gupta, P., Gupta, V., Singh, C. M., & Singhal, L. (2023) · Cureus · doi:10.7759/cureus.41295 · Cited by 27 · see citing works

Understanding low COVID-19 booster uptake among US adults

Jacobs, E. T., Cordova-Marks, F. M., Farland, L. V., Ernst, K. C., Andrews, J., Vu, S., Heslin, K. M., Catalfamo, C. J., Chen, Z., & Pogreba-Brown, K. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.080 · Cited by 27 · see citing works

Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants

Ye, Z., Bonam, S. R., McKay, L. G. A., Plante, J. A., Walker, J. L., Zhao, Y., Huang, C., Chen, J., Xu, C., Li, Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2311752120 · Cited by 25 · see citing works

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variantPreprint

Scheaffer, S. M., Lee, D. W., Whitener, B. M., Ying, B., Wu, K., Jani, H., Martin, P., Amato, N. J., Avena, L. E., Berrueta, D. M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.12.507614 · Cited by 26 · see citing works

Vaccination for Patients Receiving Dialysis

Sam, R., Rankin, L. I., Ulasi, I., Frantzen, L., Nitsch, D., Henner, D. E., Molony, D. A., Wagner, J. E., Chen, J., Agarwal, S. K., et al. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100775 · Cited by 25 · see citing works

Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2

Lenart, K., Cerveira, R. A., Hellgren, F., Ols, S., Sheward, D. J., Kim, C., Cagigi, A., Gagné, M., Davis, B. J., Germosen, D., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00806-2 · Cited by 26 · see citing works

Computationally designed proteins mimic antibody immune evasion in viral evolution

Youssef, N., Gurev, S. F., Ghantous, F., Brock, K. P., Jaimes, J. A., Thadani, N. N., Dauphin, A., Sherman, A. C., Yurkovetskiy, L., Soto, D., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.015 · Cited by 25 · see citing works

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19

Chalkias, S., Harper, C., Vrbicky, K. W., Walsh, S. R., Essink, B. J., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac492.1873

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Preprint

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2022) · medRxiv · doi:10.1101/2022.12.11.22283166 · Cited by 10 · see citing works

A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273Preprint

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bethune, C., Nally, R., Bula, M., Kalra, P. A., Clark, R., Dargan, P. I., Boffito, M., et al. (2023) · medRxiv · doi:10.1101/2023.01.24.23284869 · Cited by 9 · see citing works

2363. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bula, M., Kalra, P. A., Dargan, P. I., Clark, R., Boffito, M., Sheridan, R., Bethune, C., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad500.1984 · Cited by 1 · see citing works

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02517-y · Cited by 73 · see citing works